Analysis of bacterial biofilms using NMR-based metabolomics by Zhang, Bo & Powers, Robert
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Robert Powers Publications Published Research - Department of Chemistry
2012
Analysis of bacterial biofilms using NMR-based
metabolomics
Bo Zhang
University of Nebraska-Lincoln
Robert Powers
University of Nebraska-Lincoln, rpowers3@unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/chemistrypowers
This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Robert Powers Publications by an authorized administrator of DigitalCommons@University
of Nebraska - Lincoln.
Zhang, Bo and Powers, Robert, "Analysis of bacterial biofilms using NMR-based metabolomics" (2012). Robert Powers Publications.
42.
http://digitalcommons.unl.edu/chemistrypowers/42
Analysis of bacterial biofilms using NMR-based metabolomics
Bo Zhang and Robert Powers*
Department of Chemistry, University of Nebraska-Lincoln, 722 Hamilton Hall, Lincoln, NE
68588-0304, USA
Abstract
Infectious diseases can be difficult to cure, especially if the pathogen forms a biofilm. After
decades of extensive research into the morphology, physiology and genomics of biofilm
formation, attention has recently been directed toward the analysis of the cellular metabolome in
order to understand the transformation of a planktonic cell to a biofilm. Metabolomics can play an
invaluable role in enhancing our understanding of the underlying biological processes related to
the structure, formation and antibiotic resistance of biofilms. A systematic view of metabolic
pathways or processes responsible for regulating this ‘social structure’ of microorganisms may
provide critical insights into biofilm-related drug resistance and lead to novel treatments. This
review will discuss the development of NMR-based metabolomics as a technology to study
medically relevant biofilms. Recent advancements from case studies reviewed in this manuscript
have shown the potential of metabolomics to shed light on numerous biological problems related
to biofilms.
Biofilms are a natural part of the ecology of the Earth, and correspond to a ‘social structure’
of microorganisms compared with a planktonic state [1–3]. They are a ubiquitous microbial
phenomenon that has been observed for bacteria, fungi, algae, yeasts, protozoa and other
organisms. In a biofilm composed of multiple diverse organisms, the interspecies interaction
can range from neutral to cooperative, to competitive, and finally, to antagonistic [4]. The
diversity of organisms able to self-organize and form biofilms is quite astounding and may
provide clues to the evolution of multicellular organisms [5]. Are biofilms a transitional
state of evolution and the basis for multicellular organisms? Or are biofilms simply a highly
organized state of single-cell organisms? The fact that biofilms provide a significant survival
advantage for adapting to the harsh and distinct environmental conditions probably explains
its broad adaptation.
How bacterial biofilms are related to human disease
The interest in biofilms is not merely a result of scientific curiosity, but is also derived from
practical concerns related to medical science [6], material engineering [7], civil engineering
[8] and others [9]. In the area of medicine, research on biofilms has focused on its
relationship to bacterial infections and drug resistance. Bacterial infections are a serious
disease and major source of deaths worldwide. Especially concerning is the growing
resistance to antibiotics that has become a major medical issue in developing countries.
Between 1980 and 1992, infectious disease deaths increased by 58%; the major contributors
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were HIV infections and AIDS, respiratory disease and bloodstream infection [10]. In 2000,
a US government report identified infectious diseases as a leading cause of death worldwide
and the third leading cause of death in the USA [11]. It has been estimated that 60–80% of
human microbial infections are caused by bacteria growing as a biofilm [12]. Certain
pathogenic biofilms are of particular concern because of the added issue of drug resistance
[13]. Multidrug-resistant pathogens, such as Enterococcus faecium, Klebsiella pneumonia,
Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter spp., are currently
infecting the majority of US hospitals [14]. As methicillin-resistant Staphylococcus aureus
(MRSA) and other resistant pathogens capable of biofilm formation continue to emerge and
propagate, understanding and circumventing biofilm resistance to antibiotics is a paramount
necessity [15].
Pathogens can be introduced into the human body through trauma, medical operations,
dental procedures or by other means [16–18]. Many surfaces of organs are heavily colonized
by microbes that have the potential to cause an infection, especially during any invasive
medical procedure. In fact, the ratio of bacteria to mammalian cells living within the human
body is ten to one, providing ample opportunity for inducing a bacterial infection from
medical procedures or trauma [19]. For example, there are over 500 species of
microorganisms identified in typical dental plaque [301]. Correspondingly, dental cavities
(caries) are commonly a result of bacterial biofilm infections [20]. Biofilms are also formed
on our tongues, cheeks, in our intestines, nasal passages, sinuses and on our skin [301].
These human microbial communities are largely unstudied and their role in infections is
largely unknown. But biofilms protect the organisms from both antimicrobials and the host
immune response, making infectious biofilms extremely difficult to treat [21]. For instance,
staphylococcal biofilm infections have a 10–1000-fold increase in antibiotic resistance [22–
24].
A serious source of biofilm infections is heart disease, which is also a major cause of
mortality in the USA [25]. Invasive surgical techniques are inevitably required to treat the
resulting symptoms of heart disease, which may lead to fatal staphylococcal-infective
endocarditis. S. aureus and S. epidermidis [26] infections stemming from implantable
medical devices (e.g., pace makers [27,28], indwelling vascular catheters [29–31], grafts
[32] and left ventricular assist devices [33–37]) are common causes of infective
endocarditis. Biofilms have also been identified on various other medical devices [12,38]
such as contact lenses, endotracheal tubes, central venous catheters, pacemakers and voice
prostheses that account for over 80% of microbial infections in the body. Catheter-
associated urinary tract infection is also a common source of biofilm infections. It has also
been suggested that autoimmune disorders, such as arthritis, chronic fatigue syndrome,
fibromyalgia, Crohn’s disease and ulcerative colitis, are caused by biofilm infections [39]. In
summary, bacterial biofilms pose a serious threat to human health because of the added
protection biofilms provide from an immune response and antibiotic treatments, the ease of
acquiring an infection from trauma and medical procedures and the rapid emergence of drug
resistance among bacteria that form biofilms.
What does a biofilm look like?
The formation and structure of bacterial biofilms have been extensively reviewed and will
only be briefly summarized here [1–3,5,8,9,40–48]. A biofilm (Figure 1) is composed of
three parts: a living or nonliving substance that provides a moist surface for attachment of
the highly organized microbial structure [49–51]; a slim-like matrix made of extracellular
DNA, proteins and polysaccharides (β (1–6)-linked N-acetylglucosamine polymer) [52,53]
that embeds the microorganism [54]; and an aggregate of microorganisms in a community
that exchange fluids, nutrients and chemical signals [46]. The life cycle of the biofilm can be
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divided into approximately three steps: attachment, growth and propagation (Figure 2). First,
a few colonies reversibly adhere to the surface via van der Waals’ forces to create an
initiation site. Attachment involves lipoteichoic acid anchored to the cell membrane [55].
This is followed by an irreversible attachment of the cells through the production of the
exopolysaccaride matrix and cell growth [51]. The cell growth is not uniform and results in
the formation of channels [9]. A combination of cell division and recruitment occurs during
the maturation stage and only biofilm shape and size are changed [9,52,56]. Finally,
detachment of individual cells and dispersion enables the biofilm to spread and colonize new
surfaces or to join another biofilm [57,58].
Biofilms are viewed as layers of bacteria encapsulated within different microenvironments
due to variations in nutrient availability [59] and differing cell densities [45,55]. Bacteria
within the biofilm core exist in a stationary or dormant growth phase [59] and are
physiologically distinct from planktonic bacteria [44,60–62]. Thus, antibiotics that target
cellular mechanisms associated with growing bacteria have diminished activity against
biofilms [63,64]. Biofilms form irregular spatial structures, which are affected by many
different ecological, biological, chemical and physical factors. The effect of these factors on
biofilm formations have been extensively investigated using a variety of computer
simulations [56,57,65–67].
Biofilm formation at the molecular level
There are some general principles regarding biofilm formation that include the need for
metabolically active bacteria for surface adhesion, the need for an adequate nutrient supply
for cell replication and exopolysaccharide production, and the fact that surfaces coated with
organic nutrients stimulate biofilm formation [2,3]. Correspondingly, bacteria biofilms
readily form on the surfaces of plastic or metal medical devices in body fluids. Some
common bacterial biofilm infections include P. aeruginosa in the lung, Escherichia coli in
the urinary tract, Vibrio cholera in the GI tract, S. epidermidis in the heart, S. aureus in
arteries, Enterococcus spp. in the urinary tract, and fungi such as Candida spp. in the GI tract
[58]. The identification of biochemical pathways critical to biofilm formation is an
important first step to being able to prevent these bacterial biofilm infections. Even with our
general understanding of the basic structure and development of bacterial biofilms,
comprehending the underlying processes responsible for inducing the transition from
planktonic cells to a biofilm is still unclear. Correspondingly, the planktonic to biofilm
transition is a complex and highly regulated process that results in a phenotypic change.
Thus, the differential expression and regulation of specific genes are associated with biofilm
formation.
Genomics & bacterial biofilms
Genomics analysis of biofilm formation started in the 1990s by first screening for biofilm-
defective mutants [68,69]. Such efforts identified a diverse number of genes required for
biofilm formation [70–76]. More recently, DNA microarray technology has been used to
identify genes up- or down-regulated in bacterial biofilms [77]. Unfortunately, there does
not appear to be a clear trend in biofilm-related genes. Instead, multiple pathways to biofilm
formation that depend on media, growth conditions and the specific organism are likely [40].
Nevertheless, some broad, common features have been observed, such as the upregulation of
genes for polysaccharide production, for various stress-induced pathways, for stationary
phase-induced genes, for a prevalence of genes of unknown function and new regulatory
pathways [77]. For example, Quoc et al. identified 19 genes in S. aureus associated with
biofilm formation that were not previously observed [74]. Again, this highlights the
difficulty encountered with identifying a uniform set of biofilm-related genes. Besides genes
involved in polysaccharide intercellular adhesion (PIA) or unknown function, the authors
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observe mutations in guanosine-dependent regulation and formation of wall teichoic acid.
The complexity of biofilm formation may be attributed to the fact that the transition from
planktonic cells to a biofilm is influenced by various and diverse environmental factors such
as ethanol [78], oleic acid [79], glucose [80], UDP-N-acetylglucosamine [81], sub-inhibitory
concentrations of some antibiotics [82], anaerobic conditions [83], iron limitation [84–86],
high osmolarity [87] and high temperature [87]. The diversity of these external stimuli
suggests a versatile regulation system.
Regulating biofilms: σ factors, two-component systems or quorum sensing
After two decades of research, multiple mechanisms of biofilm regulation have been
proposed: σ factors, two-component systems (TCSs) or quorum sensing. σ factors control
the expression of various genes, including virulence factors and global regulators, which are
related to biofilm formation [88–90]. They are activated when bacteria sense environmental
conditions that induce stress (e.g., heat shock, nitrogen-limitation, starvation and high
osmolarity) [91]. TCSs are an alternative stimulus–response coupling mechanism that have
been shown to regulate diverse metabolic processes, such as the bacterial cell cycle, cell–cell
communication, and virulence factors in biofilm formation [92]. In a TCS, a ligand or a
signal molecule can stimulate a histidine kinase sensor protein, which undergoes
autophosphorylation at a conserved histidine residue. The phosphoryl group is then
transferred to the cognate response regulator, which can activate or repress transcription of
the target genes [92,93]. Conversely, quorum sensing uses signal molecules for bacterial
intercellular communication. Quorum sensing enables bacteria to ‘sense’ cell density and
coordinate behavior in response to nutrient availability, toxic compounds, host–immune
response, and defense [94,95]. In Gram-negative bacteria, N-acyl homoserine lactones
(autoinducer-1 [AI-1]) have been identified as the signal molecules [96]. AI-1 is synthesized
and sensed by analogous LuxI and LuxR regulatory proteins. The specific AI-1 molecule
varies between Gram-negative organisms. For Gram-positive bacteria, autoinducer peptides
(with no conserved sequence) have been identified as a signal molecule that involves a two-
component signal-transduction system [97]. Furanosyl borate diester (autoinducer-2 [AI-2])
has been identified as a universal interspecies signal molecule that regulates biofilm
formation in over 55 Gram-positive and -negative species [98]. Figure 3 illustrates some
common regulatory mechanisms of the planktonic to biofilm transition.
Targeting biofilm regulation systems for drug discovery
TCS and autoinducers are promising drug targets for biofilms because of the essential role in
cell growth regulation and the unique mechanisms of action compared with conventional
antibiotics [99–102]. Importantly, proteins from TCS and quorum sensing are absent in
humans, minimizing toxicity concerns. In addition, both biological processes are based on
ligand-receptor interactions, which are typical targets for drug discovery and have a
reasonable likelihood of success. Histidine kinases and response regulators, such as WalK/
WalR, YhcS/YhcR81, HP165/HP166 and MtrB/MtrA, are potential drug targets for bacteria
pathogens [102]. Targeting the kinase domain appears to suffer from poor selectivity, but
targeting the sensor domain may prove more successful. Furthermore, targeting nonessential
TCS proteins that regulate virulence, such as GacS/GacA, PhoQ/PhoP and CorS/CorR, has
demonstrated some initial positive results [102].
Alternatively, quorum sensing may be interrupted by targeting the LuxI, LuxR or LuxS
transcriptional regulators [103,104], AIP receptors [101] or Lsr transporters [98]. A common
approach is to use the three classes of autoinducers as chemical templates to design agonists
or antagonists as a starting point for drug design (Figure 4) [105,106]. For instance, TCS
proteins QseC/QseB from E. coli (EHEC) O157:H7 that responds to AI-3, epinephrine and
norepinephrine, are inhibited by LED209 (N-phenyl-4-[[(phenylamino)thioxomethyl]
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amino]-benzenesulfonamide) [107]. Additionally, the RNAIII-inhibiting peptide (RIP;
YSPWTNF-NH2) is an inhibitor of the staphylococcal TRAP/agr system, which is regulated
by autoinducer RNAIII-activating protein [108]. RIP was shown to be active against MRSA
graft infections. There has also been significant effort in the design of AI-2 analogs as novel
antibiotics because of AI-2’s broad activity against multiple species [109,110]. For instance
Roy et al. explored the activity of C-1 alkyl analogs of AI-2 against multiple bacterial
species [110]. Ethyl-4,5-dihydroxy-2,3-pentanedione (DPD) was found to inhibit quorum
sensing in both E. coli and Salmonella typhimurium. In addition, Rui et al. explored DPD
analogs with a new stereocenter at C-5 (4S, 5R)-DHD [111]. The compound was also shown
to be active against both E. coli and Vibrio harveyi. Conversely, Tsuchikama et al.
synthesized carbocyclic analogues of DPD that were inactive against S. typhimurium and V.
harveyi, suggesting the importance of the linear form of DPD and the heterocyclic oxygen
atom [112]. Similarly, Lowery et al. explored a variety of DPD analogs that resulted in a
uniform lower activity, which highlights the general challenge in evolving a small chemical
template into a drug [113]. Nevertheless, the unique mechanism of action for TCS and
autoinducer targets holds the promise of a valuable new class of drugs that may circumvent
biofilm resistance to antibiotics (Figure 4).
An overview of metabolomics
What is metabolomics?
Metabolomics is the study of metabolites, such as amino acids, carbohydrates and lipids that
are the end products of cellular regulatory processes, as well as intermediates and other
signaling molecules [114,115]. The metabolome is the complete collection of all
metabolites within a biological cell compartment, cell, tissue, organ or organism examined
in the form of a cellular extract or biofluid [116,117]. In general, a molecular weight of 1
kDa is the typical limit that separates metabolites from macromolecules [118].
There are many differences between conventional metabolite measurements and
metabolomics. First, metabolomics focuses on a global or broad-based analysis of
metabolites through a high-throughput detection methodology compared with a limited and
directed analysis of a specific number of individual metabolites [115]. In general,
metabolomics does not require the complete separation of individual metabolites. Instead, it
captures a ‘snapshot’ or ‘fingerprint’ of the state of the metabolome. Thus, metabolomics
simplifies metabolite detection by using a single analytical technique to characterize the
state of the metabolome. In this manner, metabolomics also provides an unbiased view of
changes in metabolism by covering all major pathways. Thus, the systematic analysis of the
ultimate response of a biological system has a better chance of describing pleiotropic effects
[115]. Second, metabolomics uses a combination of multiple methodologies, such as cellular
biology, instrumental analysis, chemometrics and bioinformatics to analyze the biological
system. This combination of techniques provides a better view of the global role that
metabolism plays in cellular functions. Again the analysis of a select set of metabolites does
not provide this sort of global picture of cellular activity. However, in theory, it should be
possible to correlate metabolic changes in a biochemical pathway with the enzymes
involved, and then to the underlying genetic alterations or changes in gene expression or
regulation [115]. A computational simulation could also integrate the experimental data to
create a systematic view of the effected biochemical pathways and, potentially, the relevant
proteins. The identification of specific proteins that are disease-related or, in this case,
related to biofilm formation, is a fundamental and critical step of the drug-discovery process.
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Benefits of metabolomics to drug discovery
Autoinducers are an excellent example of the significant roles that small molecules can play
in bacterial biofilms, where mimicking or inhibiting the mode of action of autoinducers is a
potential drug-discovery target. Other inter- or intra-cellular small-molecular-weight
molecules may have similar roles in the initiation, progression and survivability of bacterial
biofilms. Specifically, biofilms are a spatial distribution of heterogeneous cells, where cells
exist in different metabolic states to maximize survival. Thus, understanding biofilms
requires a comprehensive characterization of the various metabolic states within a complex
cellular community. Correspondingly, metabolomics provides a systematic approach to
explain this complex system [119,120].
Compared with genes and proteins, primary metabolites are highly conserved between
various cells and organisms [121]. In a similar manner to gene expression, some of the key
metabolites, nutrients and signal molecules (autoinducers) have been shown to significantly
influence biofilm formation [122]. Thus, metabolite quantification and the pathway
modeling of complex biological systems is useful for exploring cell behavior in establishing
a biofilm community. Furthermore, metabolomics is an invaluable approach for
investigating antibiotic resistance in biofilms. By generating a network of metabolites
affected by the drug treatment, it is possible to predict the antibiotic’s mechanism of action
[123]. Additionally, the phenotype of antibiotic resistance and biofilm strains can be
characterized through their relative metabolome differences. Similarly, monitoring
metabolic changes can be used to investigate the effects of other environmental stimuli on
biofilm formation [124]. Metabolomics can also be used for detecting disease biomarkers
[125] and as a supplementary tool for proteomics and transcriptomics. The linkage between
metabolomics, mRNA and protein expression makes it possible to visualize the biological
state of an organism [126].
Metabolomics is the bridge between genotype and phenotype [115]. Correspondingly,
metabolomics provides a better understanding of a disease since it links the pathology to
actual changes in the activity of biological processes. Metabolomics provides an approach to
diagnose a disease, monitor its progression, evaluate a response to therapy, and identify
potential novel drug targets. Thus, metabolomics has a wide range of applications in drug
discovery [127], including toxicology [128] and functional genomics [126].
Achievements of NMR-based metabolomics
NMR metabolomics has been applied to identify biomarkers for cardiac disease [129,130],
liver disease [131], respiratory disease [132,133], cancer [134–137] and CNS disorders
[138–141], among others. NMR metabolomics provides a means to differentiate between a
disease and healthy state or between drug treated and untreated. Drug discovery or
chemical-lead identification is then based on observing the metabolome change from a
disease state to a healthy state or by simply observing that a compound changes the
metabolome. For example, Tizianni et al. describes using NMR metabolomics in a high-
throughput screening platform (96-well plates) to identify kinase inhibitors [142]. They
demonstrate that changes in the lactate/pyruvate ratio in human leukemia cells (CCRF-
CEM) and human ovarian cancer cells (SKOV-3) was successful in identifying inhibitors of
eEF-2, NF-kB, MK2, PKA, PKC and PKG kinases. Similarly, Halouska et al. demonstrate
that the in vivo mechanism of action of a chemical lead can be inferred by comparing the
metabolome changes to a known drug [123]. If two or more drugs have a similar impact on
the metabolome then the compounds share a similar target. Additionally, NMR
metabolomics is also widely used for drug development and personalized medicine [143–
145]. The consortium for metabonomic toxicology, an organization of major pharmaceutical
companies, was formed to share metabolomics data from drug studies to characterize
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metabolites associated with kidney or liver toxicity. The overall protocol for toxicity
analysis is comparable to drug discovery and lead identification. Specifically, biofluid (e.g.,
urine, serum and saliva) metabolites from animals or patients undergoing drug treatment are
analyzed by NMR to identify metabolites known to be associated with drug toxicity or
disease biomarkers. If the biofluid metabolites reveal the presence of drug toxicity or the
lack of drug efficacy, then an alternative treatment can be prescribed.
Designing a metabolomics experiment: what information is desired?
Metabolomics is routinely combined with alternative strategies to resolve a biological
problem and to generate a comprehensive analysis. Although different strategies may
require alternative experiments and data analysis, targeted metabolite analysis, metabolic
profiling and metabolic fingerprinting share the same general workflow from sample
preparation to data collection and analysis. Targeted metabolite analysis is the exclusive
study of the direct product of a corresponding enzyme or protein [116]. Metabolic profiling
is the identification and quantification of a set of predefined metabolites in a biological
sample [146]. The metabolites may belong to a specific class of compounds or a particular
metabolic pathway. As an illustration, metabolic fingerprinting can be used to probe
different metabolic phenotypes. Metabolic profiling can then be used to provide a detailed
analysis of specific metabolite changes between the two phenotypes. Metabolomics can also
be referred to as ‘metabolic fingerprinting’ [147], and is generally designed to rapidly
classify biological samples. The combination of different strategies makes metabolomics a
flexible and versatile technique for the analysis of various biological systems, such as
bacterial biofilms [148,149]. The NMR metabolomics methodologies described for drug
discovery are equally applicable to investigating bacterial biofilms, for identifying new drug
targets and chemical leads, and evolving lead candidates into new drugs. Again,
characterizing and comparing the metabolomic differences between planktonic cells and
biofilms provides a means to identify active and relevant biological processes associated
with biofilm formation. Correspondingly, proteins involved in these pathways are potential
drug targets. Identifying and validating drug leads can then be accomplished by observing
chemical-induced changes in the metabolome related to biofilm formation.
Designing a metabolomics experiment: what steps need to be taken?
NMR-based metabolomics generally refers to a comprehensive approach to the analysis of
metabolomic samples that include specific NMR experiments, sample preparation protocols,
and multivariate statistical analysis [150–152]. NMR spectroscopy is used to characterize
the metabolic samples by providing both qualitative and quantitative data [117]. NMR-based
metabolomics of bacterial biofilms consist of the general procedures outlined in Figure 5:
prepare the metabolic samples by culturing the desired bacterial strains under identical
conditions (the only variable should be the specific environmental or genetic factor being
investigated); prepare the NMR samples by lysing the cells, extracting the metabolites and
removing cell debris; detect the metabolites through various NMR techniques; and perform
spectral processing, data normalization, statistical analysis and metabolite identification. The
success of metabolomics largely depends on accomplishing each step in a highly controlled
and uniform manner. Variations in the NMR metabolomics data should result from relevant
biological differences between the samples as opposed to artifacts introduced from sample
or data handling. For example, extracting the metabolites from the lysed cells should occur
quickly and at low temperatures to avoid changes to the metabolome that results from the
process of harvesting the cells. In effect, all potential variables, such as the number of cells,
growth phase, culture media, experimental conditions, bacterial strain and time, need to
remain constant between all bacterial samples [153]. Again, the only difference between the
various bacterial cultures should be the specific environmental or genetic factor being
investigated. Uniformity is the key to a successful metabolomics experiment. It is
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impractical to investigate a heterogeneous sample composed of multiple bacterial organisms
since there is no mechanism to associate the majority of the commonly observed metabolites
to a specific organism. Alternatively, using flow cytometry or other techniques [154] to
separate the cells prior to investigating the metabolome does not solve the problem. The
results would be invalid because the time required and the process of separating the cells
would perturb the state of the cells and, correspondingly, the metabolome.
Designing a metabolomics experiment: what model is used?
Fundamental to a metabolomics study is the identification of the classes or groups of
bacterial cells that will be compared. A straightforward application is the comparison
between two groups, a bacterial strain in its planktonic state (class one) and its biofilm state
(class two). Models of higher complexity include even more classes. For example, Figure 6
illustrates the application of metabolomics to monitor in vivo drug activity. The diagram
illustrates the general analysis of clustering patterns in a principal component analysis
(PCA) scores plot. In a scores plot, the metabolome of four different classes are compared:
wild-type cells; mutant cells in which the drug-target has been genetically knocked-out;
wild-type cells treated with the drug; and mutant cells treated with the drug. The activity and
selectivity of the drug is determined by the relative similarity of the four different
metabolomes as described in Figure 6. As an illustration, a drug is selective and active if the
metabolome of the wildtype cells treated with the drug clusters together with the
metabolome obtained from the mutant cells with and without drug treatment, where this
cluster forms a separate cluster from the wild-type cells without the drug treatment (Figure
6B). These results indicate the protein target in the wild-type cells was chemically
inactivated since the metabolome is identical to the mutant cells where the protein was
genetically inactivated. It also differs from the wild-type cells without the drug treatment
where the protein is still active. The drug is selective because there is no difference between
the metabolomes for the mutant cells with or without drug treatment. This analysis can be
easily generalized. The ‘drug’ in this scenario can also be taken as any environmental
condition, while the ‘mutant’ can be taken as the drug target or any knockout, repressed or
overexpressed gene.
Metabolomics sample preparation
Metabolite sample preparation includes cell quenching, cell harvesting, cell disruption and
metabolite extraction. An important advantage of NMR-based metabolomics is the minimal
and relatively simple sample preparation protocol. Nevertheless, the details of the procedure
influence the accuracy, reliability and reproducibility of the metabolomics data [117].
Different approaches to sample preparation have various advantages in terms of speed,
capability, consistency, efficiency and metabolite recovery yield [155–157]. Since biofilms
can form on a wide range of surfaces or habitats, the experimental conditions for growing
and harvesting cells can be highly variable. Therefore, this review will focus on a general
discussion of sampling methods for biofilm-related planktonic cells.
A proper metabolite extraction technique is critical
A very critical issue in sample preparation is the need to rapidly and efficiently quench all
enzymatic and biological activities in order to capture an accurate ‘snap-shot’ of the
metabolome. This is because metabolites, such as pyruvate, fumarate, oxoglutarate,
phosphoenolpyruvate, fructose-6-phosphate and others, have a rapid turnover rate [158]. In
addition, it is important to avoid inducing a stress response or cell death that would
completely invalidate the study. Thus, a quick quenching step that involves reducing the cell
temperature has been shown to be a useful approach to slow down enzyme activity within a
cell [155]. Methanol is commonly used because of its low freezing point and minimal
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toxicity relative to other organic solvents [156]. However, methanol may only be suitable for
Gram-positive bacteria or fungi due to the possibility of cell leakage and the loss of
metabolites during the quenching and washing steps [158]. Choosing the proper metabolite
extraction protocol is extremely critical since it influences the efficiency and accuracy of the
entire metabolomics experiment.
Improperly removing the cell growth medium and washing the cells is an easy way to
contaminate the metabolomic samples and generate unreliable data. Filtration and
centrifugation are the two main methods of removing the culture medium before collecting
the metabolome. Centrifugation takes longer so there are concerns regarding induced stress
and metabolome changes, but it has a higher consistency in sample preparation. Conversely,
filtration is significantly faster, and it is also easier to quench cells on a filter membrane.
However, there are also practical concerns with uniformly and consistently retrieving all the
frozen cells from the filter paper. Nevertheless, filtration quenching was demonstrated to
have the highest yield for an S. aureus metabolomics study [159]. An NMR-based
metabolomics study of P. pastoris applied a single centrifugation step and demonstrated that
there was no benefit to including an additional washing step in the quenching process [160].
Directly growing E. coli cells on filter paper may provide an efficient and fast approach to
quench cells and extract the metabolome [161]. To date, the choice of technique to separate
and wash cells is still very flexible, which implies a necessary optimization step for any
metabolomics study. An inability to efficiently arrest all cell processes and purify the cells
without inducing leakage or lysis will inadvertently lead to undesirable changes in the state
of the system and the metabolome. Thus, choosing system-appropriate washing, quenching
and cell separation protocols is the first and most critical step of a metabolomic project and
will determine the validity of the entire study.
Cell lysis and metabolite extraction can sometimes be carried out simultaneously. Both
mechanical disruptions, such as the Fast-Prep® system or organic solvent-based methods are
widely used [157,162]. Trichloroacetic acid is a traditional approach for lysing cells from
filter paper, but trichloroacetic acid causes a significant background for metabolomics data
because it also degrades the filter paper [158]. The optimal extraction buffer should: extract
the largest number of metabolites; be nonselective and not exclude molecules with particular
physical or chemical properties; and be nondestructive, as well as not modify metabolites
through chemical or physical means [163]. Since metabolites are normally dissolved in a
D2O buffer or CDCl3 for NMR, choosing alternative extraction solvents is not particularly
beneficial. A common extraction solvent is a 5:2:2 v/v mixture of methanol, chloroform and
water [164]. Other extraction mixtures include a 1:1 v/v mixture of methanol and
chloroform, or water and chloroform for metabolite extractions that include lipids [165].
NMR experiments for metabolomics
There are many practical challenges encountered when studying the bacterial metabolome.
A cellular metabolome can contain upwards of thousands of metabolites, with a 7–9 order of
magnitude range in concentrations (i.e., picomoles to millimoles) [166]. Therefore, it is
generally not possible to analyze all cellular metabolites in a single experiment. Also,
cellular metabolism is very sensitive to environmental changes, in which the measurement
and sampling process can influence the metabolome. Thus, metabolomic measurements are
also perturbed by including separation techniques. Correspondingly, each biological system
requires experimental optimization to accurately study its metabolome.
NMR- or MS-based metabolomics?
MS and NMR are the primary analytical techniques used for metabolite detection. MS
measures the mass-to-charge ratio of charged molecules that can be used to determine the
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elemental composition and elucidate the chemical structure of molecules. While an exact
mass is determined by MS, the limited molecular-weight dispersion of the metabolome
generally requires the use of chromatography [167]. GC, HPLC and CE are common
separation techniques used in MS-based metabolomics [168,169]. Unfortunately, the use of
chromatography to separate metabolites inevitably leads to changes in the metabolome. The
amount that is recovered from the chromatography step will vary for each metabolite, where
some metabolites will be lost or chemically modified. MS also requires ionization of the
molecule for detection with the corresponding uncertainty that a specific metabolite will
ionize. Furthermore, determining a concentration for each metabolite by MS is particularly
challenging.
Conversely, NMR determines a molecular structure by measuring nuclear chemical shifts
within a magnetic field [170]. Three valuable pieces of information are obtainable from a
single peak in an NMR spectrum (Figure 7). The chemical shift is related to the local
chemical environment of that specific nucleus (e.g., 1H, 13C and 15N), and the peak-splitting
(J-coupling) identifies chemically bonded nuclei, which are both used to identify the
chemical structure of the metabolite [170]. Importantly, the peak intensity is directly
proportional to the metabolite’s concentration. Typically, multiple distinct NMR resonances
are observed per molecule, which eliminates the need for chromatographic separation and
increases the accuracy of metabolite identification.
MS is significantly more sensitive than NMR and covers a wider diversity of the
metabolome, although the use of cryogenic probes has significantly increased the sensitivity
of NMR by a factor of four [171]. In effect, NMR only detects the most abundant
metabolites that are present at concentrations greater than 1 to 5 µM. 1H NMR is typically
used for metabolomics since 1H NMR is 64-times more sensitive than 13C NMR.
Nevertheless, NMR cryoprobes can still be used to detect metabolites using naturally
occurring 13C, which has an abundance of only 1.1% (12C is not detectable by NMR)
[172,173]. MS is a destructive technique, but it requires a significantly lower sample amount
(<100 µl) compared with NMR (600 µl). Correspondingly, both approaches are
complementary to each other and contribute inherently distinct information to the analysis of
a metabolome [174]. The complementary nature of MS and NMR has been demonstrated by
a number of metabolomic studies using both techniques [175–179]. In effect, the MS and the
NMR data can be combined to create a 3D scores plot. The added dimensionality from
complementary data may provide the additional resolution necessary to differentiate
between multiple classes or groups.
1D, 2D & solid-state NMR techniques for metabolomics
The application of NMR spectroscopy for metabolomics can be categorized into one of three
groups, 1D NMR, 2D NMR and solid-state NMR [170]. 1D and 2D solution-state 1H NMR
experiments are commonly used for global metabolomics analysis of bacterial cell extracts
[180]. Conversely, solid-state NMR can be used to analyze intact cells [181–183]. In
addition to 1H, other nuclei are also used in 1D NMR-based metabolomics, such as the
metabolic profiling of the carbohydrate cycle using 1D 13C NMR [184,185], or tissue
metabolism using 1D 31P NMR [186].
A typical 1D 1H NMR spectrum of a bacterial cell lysate may contain thousands of sharp
lines from low-molecular weight metabolites (Figure 7) [117]. The entire 1D 1H NMR
spectrum is used as a ‘fingerprint’ to characterize the state of the bacterial cell. A global
investigation of the metabolome is based on a comparative analysis of the features present or
absent in each 1D 1H NMR spectrum. A global metabolomic analysis is based on how
similar or how different the 1D 1H NMR spectra are between each class or group. It is not
necessary to assign each 1D 1H NMR spectrum to identify and quantify all the metabolites
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present in each sample. Overlapping these relevant NMR resonances and interfering with the
analysis may be broad bands from proteins or other biomolecules, which can be readily
removed by using a Carr–Purcell–Meiboom–Gill (CPMG) spin-echo sequence [187]. The
CPMG pulse sequence takes advantage of the large difference in T2 relaxation times
between small-molecular-weight metabolites and large-molecular weight biomolecules. The
NMR resonances from the biomolecules rapidly decay during the CPMG pulse.
Alternatively, proteins and other biomolecules can be removed by an appropriate choice of
extraction solvents [188,189]. The large interfering signal from water or other buffer
components is also eliminated by the use of appropriate NMR solvent-suppression methods
and a 100% deuterated buffer [190]. The water NMR resonance is set in the center of the
spectrum where selective irradiation and gradient pulses suppress the solvent peak while
leaving all other peaks unaffected. In effect, any resonance in the 1D 1H NMR spectrum that
does not originate from the bacterial metabolome will generate a ‘false feature’ that needs to
be removed. NMR resonances originating from proteins or solvents are likely to be variable
and dominate the spectra relative to metabolite signals. This will lead to an erroneous
interpretation of the 1D 1H NMR spectra and incorrect sample classification. For instance,
replicate samples may not cluster together because of a significant variation in the peak
height and peak shape of the water resonance despite the overall similarity in all the
metabolite NMR peaks.
High-resolution magic angle spinning (HR-MAS) is used to generate in vivo 1D 1H spectra
of solids comparable to solution-state NMR [191]. Thus, small, intact and untreated cells or
tissues can be directly analyzed by HR-MAS by spinning samples at speeds between 4 and
12 kHz at the ‘magic’ angle of 54.7° relative to the external magnetic field. Spinning the
sample significantly reduces NMR line widths by averaging out chemical shift anisotropy,
magnetic susceptibility, and dipolar coupling that are prominent in solid samples [170].
Assigning a 1D 1H NMR spectrum to identify the metabolites present in a sample is
challenging because of the large number of peaks, the significant overlap in peaks, the high
chemical shift degeneracy (multiple metabolites have some chemical shifts in common), and
an incomplete database of NMR reference spectra for metabolites. Again, assigning a 1D 1H
NMR spectrum is not necessary for a global analysis of the metabolome, but identifying the
specific metabolites that are changing and are the main contributors to class distinction is
extremely valuable for understanding the underlying biological differences. Statistical total
correlation spectroscopy (STOCSY) can be used to associate multiple NMR peaks from the
same molecule in a complex mixture [192]. This significantly simplifies the assignment
problem since most, if not all, of the NMR resonances for a given metabolite can be used
together in a database search. A positive identification only occurs when all of the observed
chemical shifts match the metabolite’s known chemical shifts in a database. In STOCSY, a
series of 1D 1H NMR spectra is converted into a pseudo-2D spectrum that is based on a
correlation of peak intensities. NMR peaks from the same metabolite will change together as
the metabolite’s concentration varies across multiple distinct classes. The statistical
heterospectroscopy (SHY) is similar in concept to STOCSY [193]. Instead of correlating
NMR peak intensities, SHY correlates chemical shifts from NMR with m/z data from MS.
Thus, SHY can improve molecular identification by directly cross-correlating NMR
chemical shifts with a molecular weight.
More commonly, 2D NMR spectroscopy improves the accuracy of metabolite assignments
by significantly increasing spectral resolution by extending chemical shift information into a
second frequency dimension. Additionally, 2D NMR experiments can identify the network
of resonances associated with a specific metabolite through J-coupling. 2D correlation
spectroscopy (COSY) and total correlation spectroscopy (TOCSY) experiments identify
spin–spin coupling connectivities that identify chemically bonded pairs of hydrogens,
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carbons or nitrogens [194,195]. To a lesser extent, 2D J-resolved NMR experiments are also
used for metabolomics studies [196]. In a 2D J-resolved NMR experiment, the data are
dispersed into two dimensions based on chemical shifts and the J-coupling pattern [197].
While it is possible to match coupling patterns to identify bonded resonances, this is
generally not practical for a complex metabolomics data set. Therefore, a 2D J-resolved
NMR experiment has significantly less information then a 2D COSY or TOCSY experiment
while requiring the same amount of experimental time. Alternatively, a 1D projection of the
2D J-resolved NMR experiment can be used to simplify the NMR spectra by removing peak
multiplicity due to J-coupling [198]. This dramatically reduces the number of peaks and
correspondingly reduces peak overlap. Removing peak splitting improves the accuracy of
metabolite identification and quantification. Of course, a single 2D NMR experiment may
require 1 h or longer to acquire compared with a few minutes for a 1D NMR experiment.
Why 2D 1H–13C heteronuclear single-quantum correlation experiments are commonly used
for metabolite identification
The 2D 1H–13C heteronuclear single-quantum correlation (HSQC) experiment correlates
the 1H and 13C chemical shifts for each C-H pair in a molecule [199]. This provides unique
information relative to the COSY, TOCSY or J-resolved experiments. In addition,
metabolite assignments are easier with a 2D 1H–13C HSQC experiment because of two
correlated and distinct chemical shift assignments, the large 13C chemical shift dispersion
and the simplified spectrum without splitting from J-coupling. However, due to the low
natural abundance (1.1%) of 13C-labeled compounds, such as 13C-methanol, 13C-CO2
[200], 13C-glycerol [201] and 13C-glucose [202] are required as a bacterial carbon source to
enhance the sensitivity of the NMR spectrum [203]. This significantly simplifies and focuses
the analysis of the metabolome. Only metabolic intermediates and products of the 13C-
labeled materials will be partially or completely enriched with 13C. Correspondingly, only
these metabolites will be observed in a 2D 1H–13C HSQC spectrum, which provides a
means to follow carbon flow through the metabolome and identify the perturbed metabolic
pathways. Standard HSQC experiments are not quantitative because of significant variability
in coupling constants and relaxation times (T1 and T2) between metabolites. Nevertheless,
the newly developed 2D extrapolated time zero 1H–13C HSQC (HSQC0) experiment allows
for the calculation of metabolite concentrations [204]. This experiment collects a series of
2D HSQC spectra with an increasing number of the core NMR pulse sequence or HSQC
block. Typically, this HSQC block is repeated from one- to three-times. The peak intensity
will decrease linearly with the number of HSQC blocks, where a linear fit and extrapolation
back to zero HSQC blocks will determine the true peak intensity and metabolite
concentration. Examples of 2D NMR spectra used to identify metabolites from biological
samples are shown in Figure 8.
Processing NMR data: binning, peak alignment, baseline correction & normalization
For chemometrics (also see the section ‘Chemometrics & bioinformatics analysis of
metabolomics data’), the 1D 1H NMR spectra are transformed into a data matrix of
integrated peak intensities and corresponding chemical shift values. These data are used to
define the classes and to identify NMR spectral features that differentiate the classes.
Unfortunately, subtle instrument, temperature and sample condition variability (e.g., pH and
ionic strength) can result in chemical shift differences between replicate samples.
Correspondingly, misalignments will occur in the NMR data matrix between these replicate
samples that will lead to clustering errors independent of any biological differences. One
approach to normalize NMR metabolomics samples is the inclusion of a known
concentration of chemical shift reference compound, such as the sodium salt of 3-
trimethylsilylpropionic acid. The 3-trimethylsilylpropionic acid peak intensity can also be
used to calibrate the concentrations of the metabolites in the biological sample. However, an
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internal reference only corrects for global differences. It does not correct for individual peak
position and shape variability due to subtle experimental differences. Instead, binning or
bucketing is commonly used to correct for peak variability between replicate samples
[205,206].
In its simplest implementation, bucketing divides the NMR spectrum into equally sized,
nonoverlapping subspectral regions with a width or bin size of 0.025 ppm. A typical 1D 1H
NMR spectrum with a width that ranges from 0 to 10 ppm will have 400 buckets. Bin sizes
typically range from 0.01 to 0.04 ppm. The peak intensity within each bucket is integrated,
and these resulting integrals are then used as input to the chemometrics analysis. In this
manner, the buckets or bins smooth out small peak variability with the expectation that the
same peaks occur in the same bucket. Unfortunately, bin edges create a second problem: the
undesirable splitting of a peak between buckets. Thus, ‘intelligent’ or ‘adaptive’ bucketing
techniques have been developed that vary the individual bin size to avoid dividing peaks
between multiple buckets [207–210]. These methods use a Gaussian function, a recursive
algorithm, optimize an objective function using a dynamic programming strategy, or use
undecimated wavelet transforms to automatically identify bin edges. In all cases, intelligent
bucketing performs significantly better than uniform bucketing, where dynamic adaptive
binning was recently shown to perform the best [210]. The use of intelligent bucketing
results in a significant improvement in replicate clustering in scores plots since it minimizes
spectral differences that are biologically irrelevant. Noise regions of the NMR spectra are
typically zeroed or removed from the bucketing [211]. Similarly, buckets resulting from
solvent or buffer peaks that are unrelated to the bacterial metabolome are also excluded.
Again, this eliminates class distinction, which results from biologically irrelevant data. In
essence, the variables used in the chemometrics analysis should be relevant to real variations
in the metabolome between the classes [153].
Peak alignment is a more robust and complex alternative to NMR binning [212–215]. The
goal is to remove the chemical shift variability between the replicate 1D 1H NMR spectra by
individually aligning each NMR peak to a representative spectrum from each class. The
approaches used include fuzzy warping, genetic algorithms, a generalized fuzzy Hough
transform approach, a reduced set mapping (PARS) algorithm, or a recursive segment-wise
peak alignment. Each approach demonstrated acceptable results on test metabolomic
samples and were shown to improve upon the results obtained from bucketing [215].
Nevertheless, intelligent bucketing is still the predominant methodology used in NMR
metabolomics.
An NMR spectrum is experimentally collected as a free induction decay (FID) that requires
further processing to convert the time-domain data into a frequency-domain spectrum
through a Fourier transform. This process can be accomplished using a variety of software
packages (Table 1). All of the software packages can import popular NMR data formats,
such as Bruker, Varian, Jeol Delta, JCAMP-DX, as well as others. Some NMR software can
process both 1D and 2D data, where others only focus on processing 1D (most popular) or
2D data sets. In addition to the Fourier transform step, the processing of NMR data may
include zero-filling, phase correction, baseline correction, applying a window function and
removal of solvent peaks. The inclusion of any of these steps induces changes in the
resulting NMR spectrum that is not biologically relevant. Thus, uniformity in the NMR
processing protocol is essential, where minimizing all spectral manipulation is ideal. In
general, phase correction is essential in order to obtain purely absorption peak shapes.
Uniform zero-filling of the NMR spectra is typically acceptable since it provides a constant
improvement in the digital resolution. Similarly, removing residual solvent peaks by simply
zeroing the corresponding region of the NMR spectrum does not have any detrimental effect
because these solvent regions are not included in the binning process. Conversely, applying
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a window function or incorporating baseline correction should be avoided, if possible, since
these processes induce significant variable changes in the NMR spectrum. The goal of a
window function is to either increase the spectral resolution or the signal-to-noise by
multiplying the FID with a mathematical function. As a result, each NMR peak shape is
artificially changed. Instead, the signal-to-noise and spectral resolution should be improved
experimentally. A baseline correction is required if the baseline for the NMR spectrum is not
flat. A flat baseline is necessary for reliable chemometrics analysis. Distorted baselines may
result from intense solvent or buffer peaks, from phasing problems, errors in the first data
points of the FID, large range of T1 values (short recycle times), or short acquisition times.
Again, baseline problems should be experimentally minimized. Nevertheless, numerous
computational approaches to obtain a flat baseline are available and include a linear or
polynomial (up to six orders) fit of the baseline, FID reconstruction and spectrum averaging.
The choice of a baseline correction method depends on the specifics of the baseline
distortion, which is typically determined by trial and error. Importantly, a single baseline
correction method must be used for an entire metabolomics dataset in order to avoid
inducing class distinctions that are primarily a result of the NMR processing protocol.
Ideally, the overall concentration of the metabolites and the corresponding signal-to-noise of
each replicate 1D 1H NMR spectrum will be essentially identical. Unfortunately, in practice,
there may be a significant variability in the signal-to-noise between replicate NMR spectra
due to random errors in cell lysing, metabolite extraction, or the number of bacterial cells
per sample. Correspondingly, the 1D 1H NMR spectra need to be normalized [216]. Center
averaging is a common normalization technique:
Equation 1
Where X̅ is the average signal intensity, σ is the standard deviation in the signal intensity,
and Xi is the signal intensity within a bin. Other normalization techniques include
normalization to a constant sum, Pareto scaling, mean centering, logarithmic scaling and
probabilistic quotient normalization. A recent analysis of NMR processing procedures by De
Meyer et al. suggests that a combination of intelligent bucketing with probabilistic quotient
normalization yields the best results [217]. Of course, it was not practical to explore all the
possible combinations of the various processing techniques and, as a result, the analysis did
not include center averaging. This highlights a particular challenge with processing NMR
metabolomics data: there is no clear consensus for an optimal protocol because of all the
possible combinations of parameters that need to be evaluated.
Chemometrics & bioinformatics analysis of metabolomics data
For a detailed understanding of a complex biological system, it is essential to follow the
response of an organism to a conditional perturbation at the transcriptome, proteome or
metabolome level [126]. Metabolic products are dependent on genotype, environment, time
and location [218]. Perturbations in any of these factors may lead to a variety of biological
changes that inadvertently affect the metabolome [126]. The primary goal of chemometrics
is to reduce the complexity of the NMR-based metabolomics data to understand these global
correlations. In essence, chemometrics identifies the major features within an NMR
spectrum, the presence or absence of peaks, the change in peak intensity or shape, or the
change in chemical shifts that differ between the various classes. A class definition can be
based on any variable that affects or changes the bacterial cell culture, such as different
bacterial strains (including wild-type and mutant cells) and different experimental conditions
(e.g., growth phase, drug dosage, media composition and pH). Bioinformatics is used to
uncover and characterize all the associated variables and to reveal the underlying
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relationships. Essentially, bioinformatics is used to identify the metabolites that correlate
with the major changes in the NMR spectra and to associate these metabolites with specific
proteins, enzymes, metabolic pathways and other biological processes.
PCA & orthogonal partial least squares discriminant analysis are the most commonly used
chemometrics techniques
For statistical modeling, PCA is the most common multivariate technique for the
comparison of metabolomic data [219]. Each multivariable (chemical shift and intensity)
NMR spectrum is converted into a single point in multidimensional Cartesian space (Figure
9). Each axis (V1, V2, V3 … Vn) corresponds to a specific chemical shift where the peak
intensity is the value along each axis. PCA determines the vector (PC1) corresponding to the
largest variation in the data and fits each NMR spectra to this vector. Each NMR spectrum is
assigned a value – prinicipal component one (PC1) based on its distance to the vector (PC1).
The process is repeated for the next largest variation (PC2) orthogonal to the first vector.
Plotting the resulting principal components (PC1 and PC2) corresponds to a scores plot,
where similar spectra (and metabolomes) cluster together in a scores plot. Spectra (and
metabolomes) obtained from different classes are expected to form separate clusters in the
scores plot. Figure 9 illustrates the hypothetical separation of class 1 from class 2 and the
relatively tight clustering of the class replicates. The class separation is based on differences
in the 1D 1H NMR spectra.
Orthogonal partial least squares discriminant analysis (OPLS-DA) is a related, but
alternative approach to PCA. Unlike PCA, OPLS-DA is a supervised method. This is an
important and significant difference. In PCA, the different classes are not identified and each
1D 1H NMR spectrum follows the protocol described above. Thus, the clustering of each
NMR spectrum in the scores plot is solely determined by the intrinsic differences and
similarities in the features of its NMR spectrum relative to all the other NMR spectra.
However, in OPLS-DA each 1D 1H NMR spectrum is assigned to one of two classes, (e.g.,
biofilm vs planktonic, healthy vs diseased, treated vs untreated, and wild-type vs mutant).
More than two class definitions can be used, but it is generally not recommended. As a
result, OPLS-DA determines the clustering patterns in the scores plot based on the NMR
spectral features and the class definition. OPLS-DA tries to maximize the separation
between the classes based on these manual class assignments, while minimizing the within
class variation. This results in tighter class clustering in the OPLS-DA scores plot relative to
PCA. Fundamentally, if two classes are defined in OPLS-DA then two clusters
corresponding to the two assigned classes will be generated in the resulting scores plot.
OPLS-DA assesses a relationship between an X matrix (NMR data) and Y matrix (the 0 or 1
class designation). Thus, OPLS-DA will only identify all the spectral features that can be
used to distinguish the two classes regardless of any real significance (e.g., noise and small
random variability in peak height). Conversely, the class separation in a PCA scores plot
depends on a combination of all principal component variables. Since OPLS-DA is a
supervised method or biased by the class assignment, it is essential that the model is
validated [153]. Is the class separation due to relevant changes in the 1D 1H NMR spectra
resulting from changes in metabolite concentrations?
The quality of the OPLS-DA model can be evaluated by multiple statistical factors and cross
validation, the goodness of fit (R2) and the quality assessment score (Q2) [220]. A good
OPLS-DA model has R2 values ≥0.5 (range of 0–1) that is conceptually similar to simple
linear regressions. Similarly, a typical value for Q2 for a biological model is ≥0.4. The leave-
one-out cross-correlation technique is commonly used to calculate Q2, where a sub-set of the
NMR spectra are left out to calculate a model that is then used to predict the left-out data
[221,222]. Q2 is the consistency between the predicted and original data. Importantly, Q2
and R2 values should only be used as a figure of merit and not validation of the model. A
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permutation tests is one approach to validate the model [221,222]. The NMR spectra
classifications are randomly assigned creating, in principle, a random data set that should
have poor class separation and low Q2 scores. The process is repeated numerous times
(>1000 permutations) until a Gaussian distribution of Q2 scores is obtained for the random
data set. The statistical significance of the model with the correct NMR spectra classification
can then be obtained by comparing the model Q2 with the random Q2 scores and calculating
a p-value. In addition to Q2, a similar validation can be achieved by using the area-under-a-
receiver-operating-characteristic curve or the number of misclassifications.
Further validation of the OPLS-DA model can be assessed by determining if the NMR
features that determine the class separation are biologically relevant. S-plots and loading
plots are additional outcomes of an OPLS-DA model. An S-plot identifies the relative
contribution of each bin (chemical shift and metabolite) to the clustering in the
corresponding scores plot, each bin with a covariance of >0.10 or <−0.10 are identified as
major contributors to the class separation [223]. Similarly, a loadings plot displays the
relative contribution of each bin to the principal components. Thus, a valid OPLS-DA model
is supported by being able to assign metabolites to the bins that are associated with the class
separation. The model is further validated if multiple bins assigned to the same metabolite
are all major contributors to the class separation. Additionally, the identification of multiple
correlated metabolites, members of the same metabolic pathway for instance, that are all
major contributors to the class separation would further strengthen the reliability of the
OPLS-DA model. Again, the overall goal of NMR-based metabolomics is to identify major
changes in the NMR spectra that can be associated to a specific set of metabolites with a
relationship to a biological process, such as bacterial biofilm formation.
A number of metabolomics software packages have been developed to automate the
chemometrics analysis by combining data normalization, data reduction, model prediction
and validation, and even metabolite identification, into a single work flow. These programs
include: Automics [224], HiRes [225], MetaboAnalyst [226] and the R-package
Metabonomic [227]. Among these, Automics is the most versatile and extensive package
and includes nine different statistical methods applicable to metabolomics data: feature
selection (Fisher’s criterion), data reduction (PCA, LDA and ULDA), unsupervised
clustering (K-Mean) and supervised regression and classification (PLS/PLS-DA, KNN,
SIMCA and SVM). Automics also incorporates processing tools to generate a STOCSY
spectrum.
Interpreting a PCA or OPLS-DA scores plot is fundamentally a cluster analysis. If two or
more classes cluster together in the scores plot, then the NMR spectra and the corresponding
metabolome are considered statistically similar. Conversely, two or more classes that form
distinct clusters indicate the samples are significantly different metabolomes. For a simple
metabolomics study that involves only two or three different types of samples, the cluster
analysis is generally straightforward. An ellipse that corresponds to the 95% confidence
limits from a normal distribution for each cluster can be used to define each class in the 2D
scores plot to visually determine class separation. Alternatively, Werth et al. [228] recently
demonstrated the application of metabolomic tree diagrams combined with standard boot-
strapping techniques [229] as a more robust statistical analysis of clustering patterns in
scores plots. Each PC value (PC1 and PC2) is treated as an axis in a Cartesian coordinate
system. An average position is calculated for each class cluster, which is then used to
calculate a Euclidean distance between each class to create a distance matrix. The cluster
centers and distances between clusters are re-calculated by randomly selecting data points
from each class. The process is repeated until 100 different distance matrices are generated,
which are then used to generate 100 tree diagrams using Phylip 3.68b [230]. A consensus
tree is created, where the bootstrap number is simply the number of times each node appears
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in all 100 trees. Bootstrap values below 50% imply a statistically insignificant separation.
Further analysis to identify the metabolic processes that led to class separation may require
bioinformatics [231]. An example 2D OPLS-DA scores plot and associated metabolomics
tree diagram is shown in Figure 10.
Metabolic pathway reconstructions have been widely employed with five major goals:
contextualization of high-throughput data; guidance of metabolic engineering; directing
hypothesis-driven discovery; interrogation of multispecies relationships; and network
property discovery [232]. NMR-based metabolomics are routinely used to generate these
metabolic networks for a particular biological system (Figure 11). The first step of the
process is to deconvolute and decode the NMR spectra. This is a difficult and time-
consuming process because the high degeneracy of NMR chemical shifts makes
unambiguously assigning an NMR resonance to a specific metabolite extremely challenging.
This is further complicated by the incompleteness of metabolomics data and by several
technical problems that include proper peak assignment [180], peak alignment [233,234],
absolute concentration determination [204,235] and intensity normalization [236]. A number
of metabolomics databases that contain NMR and MS spectra with the associated
assignments are available: Metabominer [237], Madison Metabolomics Consortium
Database [238], BioMagResBank [239] and Human Metabolome Database [240]. Some
efforts to automate the process have also been made [180,224].
The next critical step is to analyze the identified metabolites and find all possible
correlations. The presence of metabolites and metabolic pathways in a particular organism
can be verified by the KEGG [241] and MetaCyc databases [242]. A metabolic network map
can then be generated using Cytoscape [243], and there are many metabolome simulators
that are useful for predicting the networks involving hundreds of metabolites [244].
Additionally, Cell Designer is a valuable diagram editor for drawing biochemical networks
[245].
Analysis of biofilms with NMR-based metabolomics
An obvious application of NMR-based metabolomics has been used to characterize the
difference in the metabolome between planktonic and biofilm cells. Gjersing et al.
applied 1H HR-MAS to study the metabolome difference between P. aeruginosa chemostat
planktonic and biofilm cells [149]. There was no apparent difference in the extracellular
metabolite composition when planktonic and biofilm cells were grown under continually
feed chemostat mode. Conversely, the 2D PCA scores plot of the intracellular metabolome
indicated a clear distinction between the batch and chemostat planktonic and biofilm cells
(Figure 12A). The corresponding loadings plot suggests major and complex differences
between the two metabolomes (Figure 12B). The metabolite differences were not analyzed
in detail, but it was noted that biofilm metabolites were generally lower in concentration,
possibly due to the cells closer to the substrate operating at a lower metabolic rate. Similarly,
Workentine et al. also used 1H NMR to characterize the phenotype of different biofilm
colonies of Pseudomonas fluorescens [246]. PCA of the 1D 1H NMR spectra yielded a 3D
PCA scores plot with distinct clustering for the four different P. fluorescens colonies (Figure
13A). The class distinction was attributed to changes in amino acids (Asp, Glu, Gly, Met,
Phe, Pro, Trp and Val) and central metabolites (acetate, glutathione and pyruvate). This is
suggestive of changes in exopolysaccharide production, response to oxidative stress, and an
impaired amino acid metabolism. Interestingly, the four different P. fluorescens phenotypes
exhibited distinctly different metal sensitivity (Figure 13B). Unfortunately, it was not
possible to determine whether the metabolome differences were a result of the different
metal sensitivity. Booth et al. also analyzed P. fluorescens cells under metal stress, but
compared planktonic to biofilms cells [148]. 1D 1H NMR was combined with GC-MS to
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obtain a detailed analysis of metabolite changes caused by the addition of copper (Figure
14). Planktonic cells responded differently to copper stress compared with biofilms.
Planktonic cells experienced an oxidative stress response as indicated by changes in the
tricarboxylic acid (TCA) cycle, glycolysis, pyruvate, nicotinate and niacotinamide
metabolism. Conversely, biofilms exhibited changes in exopolysaccharide-related
metabolism suggestive of a protective response instead of the reactive changes that occurred
in planktonic cells.
Demonstrating a difference between planktonic cells and biofilms by NMR is an important
step towards an application in drug discovery. Does a chemical lead inhibit metabolic
pathways associated with biofilm formation? Does drug treatment result in a metabolome
more similar to planktonic cells despite conditions that induce biofilm formation?
Comparing the metabolome of planktonic cells with and without drug treatment may
provide an answer to these key questions. Furthermore, the comparative analysis of
planktonic cells and biofilms has already identified changes in the activity of specific
cellular process correlated with biofilm formation. Thus, proteins essential to
exopolysaccharide production and the response to oxidative stress may be novel targets for
disrupting biofilm formation. Additionally, the metabolome differences between planktonic
cells and biofilms can be used as a diagnostic tool and in the design of treatments. As an
illustration, Hall-Stoodley et al. describe the application of microbiological culture,
polymerase-chain reaction-based diagnostics, direct microscopic examination, fluorescence
in situ hybridization and immunostaining to characterize middle-ear mucosa biopsy
specimens for biofilm morphology [247]. The authors concluded that chronic otitis media in
children that require tympanostomy tube placement is biofilm related. NMR metabolomics
could provide a similar analysis of biopsy samples. The treatment of biofilm infections that
have colonized on medical implants often requires the removal of the infected device [149].
Investigating changes in bacterial metabolomes in response to the different surfaces (e.g.,
metals and polymers) may contribute to the development of novel materials resistant to
biofilm formation [248,249]. Coating or embedding medical devices with antibiotics is a
common approach to prevent biofilm infections, but the overuse of antibiotics incurs the risk
of inducing the rapid development of resistance [250,251].
Besides characterizing cellular differences through metabolomics, NMR can also be used to
explore the overall structure and function of biofilms. Vogt et al. used NMR to describe
differences in metabolite diffusion within a biofilm [252]. Pulsed-field gradient NMR was
used to measure diffusion coefficients for slowly moving water and other components in a P.
aeruginosa biofilm. Five groups of components including water, glycerol, and
polysaccharides, were observed with diffusion coefficients ranging from 1.8 × 10−9 to 5 ×
10−13 (m2s−1) that indicate locations in the biofilm pores or the extracellular polymeric
substance. Correspondingly, the complicated structure of a biofilm is a major obstacle to
successful treatment with antibiotics. As the above NMR experiment suggests, a biofilm is a
diffusion barrier that hinders the infusion and dispersion of antibiotics within a biofilm
[253]. This also suggests that the in vivo activity of a chemical lead is determined by both its
efficient dispersion throughout the biofilm in addition to its intrinsic inhibitor activity.
A recent study by Rogers et al. analyzed the synergistic activity of 2-aminoimidazole-
derived compounds, a new class of antibiofilm agents that disperse biofilms [254].
Combining a 2-aminoimidazole-derived compound with known antibiotics resulted in a two-
to eight-fold reduction in MICs against biofilms of P. aeruginosa, Acinetobacter baumannii,
Bordetella bronchiseptica and S. aureus. Importantly, the antibiofilm agent actually
resensitized MRSA. Walencka et al. observed a synergy between salvipisone and
aethiopinone from Salvia sclarea hairy roots with β-lactam antibiotics. Improved activity
was observed against MRSA and multiresistant S. epidermidis (i.e., MRSE) [255].
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Salvipisone and aethiopinone are postulated to function by altering cell surface
hydrophobicity and cell wall/membrane permeability.
NMR metabolomics has also been used to investigate the mechanism by which S.
epidermidis and S. aureus respond to a diverse set of environmental signals to induce the
planktonic to biofilm transition. Bacteria have been shown to form biofilms in response to
variations in ethanol, oleic acid, glucose, UDP-N-acetylglucosamine, subinhibitory
concentrations of some antibiotics, anaerobic conditions, iron limitation, high osmolarity
and high temperature. Instead of numerous distinct signaling pathways, a series of detailed
NMR and molecular biology experiments has demonstrated the presence of a single flexible
metabolic signaling pathway centered on the TCA cycle [124,202,256]. 1D 1H NMR
combined with OPLS-DA was used to compare the metabolome of wild-type S. epidermidis
1457 and an aconitase mutant strain 1457-acnA::tetM under various environmental stressors
known to induce biofilm formation (Figure 10). The change in the metabolome of wild-type
S. epidermidis 1457 in the presence of 4% ethanol, 2% glucose, Fe-limitation and 0.06 µg/
ml of tetracycline was shown to be essentially identical to the aconitase mutant with an
inactive TCA cycle. No change in the metabolome was observed for the aconitase mutant
with or without the addition of environmental stress factors. 2D 1H–13C HSQC experiments
combined with bacteria grown in the presence of 13C-glucose were used to generate a
detailed analysis of the changes in the S. epidermidis metabolome (Figure 11). Consistent
with the global changes in the metabolome, wild-type S. epidermidis in the presence of the
environmental stressors induced the downregulation of metabolites associated with the TCA
cycle and the upregulation of metabolites related to PIA production. These results suggest
that biofilm formation is regulated by the activity of the TCA cycle. Inactivating the TCA
cycle allows the shuttling of key metabolites into PIA production, which is generally
necessary for biofilm formation. Similarly, White et al. compared the metabolome of wild-
type Salmonella and a CsgD deletion mutant that prevents production of an extracellular
matrix [257]. GC–MS and NMR were used to analyze the metabolome along with an
analysis of gene expression. Metabolites associated with glucogenesis and major
osmoprotectants were upregulated in wild-type Salmonella; whereas metabolites associated
with the TCA cycle were upregulated in the mutant. Again, this is consistent with the TCA
cycle activity regulating biofilm formation. These results suggest that agonists of the TCA
cycle would interfere with biofilm formation. Diets or drugs that modulate the nutrient
environment may be an approach to prevent bacterial biofilm. As an example, iron limitation
downregulates the TCA cycle and induces biofilm formation [258]. The major source of
morbidity and mortality in cystic fibrosis patients is P. aeruginosa biofilms formed in the
lung. High iron concentrations inhibit P. aeruginosa biofilms, where chelated sources of iron
combined with antibiotics hold promise as a treatment for cystic fibrosis [259,260].
Metabolomics can also be used to construct metabolic pathways, with contributions from
proteomics and genomics information. Liebeke et al. provided a time-resolved analysis of S.
aureus during the transition from exponential growth to glucose starvation [261]. The
activity of more than 500 proteins and the concentration of 94 metabolites were followed.
1D 1H NMR was used for the quantification of compounds in the media before inoculation,
and at defined time points during cell growth. Intracellular metabolites were measured by
GC–MS/LC–MS. In general, changes in the metabolome correlated with changes in the
proteome, where the metabolome displayed a larger dynamic range. The most dramatic
changes were observed for amino acids. During initial cell growth, glycolysis and protein
synthesis were highly active, but as glucose was exhausted gluconeogenesis and the TCA
cycle were activated. Again, this is consistent with the TCA cycle activity regulating biofilm
formation due to variations in glucose concentrations [80]. Metabolomics is a valuable
approach to characterize the state of a system. Nevertheless, incorporating additional
complementary data, such as proteomics, significantly enhances the reliability of the
Zhang and Powers Page 19
Future Med Chem. Author manuscript; available in PMC 2013 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
information. Observing a correlation between a metabolite’s concentration and a protein’s
expression level further substantiates the importance and relevance of the protein to the
system, such as biofilm formation. From a drug-discovery perspective, this provides
substantial corroboration of a potentially new drug-discovery target.
Conclusion
NMR metabolomics can be used to characterize different cell phenotypes, to investigate the
underlying biology of biofilm formation, explore the impact of various environmental stress
factors on cell biology, analyze the effect of gene mutations, investigate the spatial and
temporal structure of a biofilm, and even to generate a 3D image. Notably, the NMR
metabolomics methodologies used to study the biochemistry of bacterial biofilms are
directly applicable to a drug-discovery effort. NMR metabolomics has been used to identify
disease biomarkers and diagnose a disease, to screen for drugs, to evaluate drug activity and
toxicity, to identify new therapeutic targets and design new treatments. While the
application of NMR for the analysis of changes in the metabolomics is a relatively new
endeavor, the technique has already made some significant contributions to our
understanding of bacterial biofilms. More importantly, NMR metabolomics holds great
promise to significantly contribute to the diagnosis and treatment of biofilm-related diseases,
where it may play an important role in personalized medicine.
Future perspective
NMR-based metabolomics is a relatively new technology for systems biology and,
correspondingly, has only had a limited use in the investigation of bacterial biofilms.
Nevertheless, the application of NMR-based metabolomics to the investigation of bacterial
biofilms is only limited by the creativity of the scientific community. In the near future, the
further development of the technology will be a primary focus. While NMR-based
metabolomics is straightforward in concept, there are numerous practical considerations that
can severely complicate the routine application of the technique. A primary issue is our
incomplete knowledge of the metabolome; extensive effort is still required to characterize
the metabolome from all organisms and populate databases with reference NMR and MS
spectra. Similarly, while some progress has been made, a metabolomics software package is
still needed that automates and standardizes the processing of metabolomics data,
chemometric analysis and model validation, and metabolite identification. Also, the efficient
and accurate extraction of metabolites from cell lysates requires continued optimization, and
varies depending on the organism under investigation. Developing these protocols is
extremely critical to the future success of metabolomics. Additional methodology
advancements that will benefit metabolomics include the routine integration of MS and
NMR data, and the efficient quantitation of metabolite concentrations from MS and 2D
NMR experiments.
Our understanding of bacteria cell biology is far from complete, where NMR-based
metabolomics will be an invaluable addition to the study of biofilms and related processes
such as programed cell death, inter-/intra-species communication and pathogenesis. The
systematic analysis of the bacterial genome, transcriptome, proteome and metabolome will
enable the construction of a detailed network to describe the regulatory and metabolic
pathways associated with biofilm formation, progression, evolution and survivability. In
addition to enhancing our basic understanding of bacterial biofilms, NMR-based
metabolomics will be an invaluable tool for drug discovery, disease diagnosis and
personalized medicine. NMR-based metabolomics can be used as part of a drug-discovery
screening protocol. Observing an induced change in the bacterial metabolome due to a drug
treatment would further validate a chemical lead identified from standard high-throughput
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screens [262,263]. In fact, Halouska et al. recently demonstrated how NMR-based
metabolomics can be used to identify the in vivo mechanism of action of a chemical lead
[123]. This addresses a major challenge with drug discovery: identifying new drugs with
activity against novel therapeutic targets that also avoid common mechanisms of resistance
or toxicity. Similarly, characterizing the metabolome of various pathogenic bacterial strains
with a correlation to drug susceptibility provides a means to personalize patient treatments.
In essence, the identification of characteristic metabolites from the biofluids of infected
patients would identify the bacterial strain and preferred form of treatment.
Acknowledgments
This manuscript was supported in part by funds from the NIH (AI087668), and from the NIH National Center for
Research Resources (P20 RR-17675).
Key Term
Metabolome The complete set of small-molecular-weight compounds (<1 kDa)
or metabolites found within bacterial cells other cellular organisms
tissues or biological samples.
Chemometrics Application of multivariate statistics to extract information and
describe a chemical or biological system. Chemometrics is used to
identify spectral features that differentiate a set of NMR spectra to
identify changes between two or more metabolomes.
Classes or groups Collections of NMR spectra obtained from replicate bacterial cell
cultures where one experimental variable differs from the other sets
of spectra.
Scores plot Each NMR spectrum is represented as a single point in a scores plot
where its relative location is dependent on the spectrum’s fit to a
predictive model. The resulting clustering pattern identifies the
relative similarity and differences between the NMR spectra.
2D 1H–13C
heteronuclear
single-quantum
correlation
spectrum
An NMR experiment that correlates the chemical shift of a proton
(1H) with the chemical shift of a carbon (13C) where the proton and
carbon are chemically bonded.
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Executive summary
▪ Bacterial biofilms are a health concern because they increase antibiotic
resistance and protect the bacteria from the host immune response system,
which may lead to a serious and untreatable infection.
▪ Bacterial biofilms can attach to a variety of surfaces that include numerous
medical devices, which is a primary source of biofilm infections.
▪ A biofilm is a highly organized microbial structure that contains a slim-like
matrix that embeds the microorganism, but allows for the exchange of fluids,
nutrients and chemical signals for cellular communication.
▪ The three main stages of a biofilm life cycle are attachment, growth and
propagation. Biofilm formation depends on the bacteria’s response to
changing environmental conditions, which is regulated by quorum sensing,
two-component systems or σ factors.
▪ Quorum sensing enables bacteria to ‘sense’ cell density and coordinate
behavior in response to nutrient availability and environmental conditions
through signal molecules. These signal molecules are prime targets for
developing drugs that inhibit biofilm formation.
▪ Metabolomics is the global analysis of small-molecule concentration changes
within a cell using NMR spectroscopy or MS. It provides a direct means of
monitoring changes in the state of the cell resulting from activities such as
drug treatments or biofilm formation.
▪ Metabolomics provides a better understanding of a disease since it links the
pathology to actual changes in the activity of biological processes. Any
observed change in the metabolome is a direct consequence of a change in
protein activity.
▪ The process of monitoring the metabolome includes rapidly quenching all
cell activities, efficiently lysing the cell, and quickly extracting the
metabolites. Speed and consistency are essential to a successful metabolic
study. The goal is to avoid perturbing the state of the metabolome during the
collection process.
▪ 1D 1H NMR, 2D 1H–13C HSQC and 2D 1H–1H TOCSY are the NMR
experiments commonly used for metabolomics. The goal of the 1D 1H NMR
experiments is to generate a ‘fingerprint’ of the state of the cellular
metabolome. The primary goal of the 2D NMR experiments is metabolite
identification.
▪ MS is also used for metabolomics, where NMR and MS are complementary
techniques.
▪ There are many considerations for the proper processing of NMR data for a
metabolomics study. These include binning, peak alignments, baseline
corrections and normalization.
▪ Chemometrics is commonly used to analyze NMR metabolomics data with
the principal goal of class discrimination. The metabolomics data are
interpreted by a simple cluster analysis, NMR spectra that yield distinct
clusters in a scores plot have different metabolomes.
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▪ A primary challenge with metabolomics is validating that the clustering
pattern in a scores plot is biologically relevant as opposed to experimentally
induced changes to the metabolome or the NMR data.
▪ A number of examples illustrating the application of NMR-based
metabolomics to the investigation of bacterial biofilms are presented.
Zhang and Powers Page 37
Future Med Chem. Author manuscript; available in PMC 2013 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Horizontal optical thin sections (0–2.6 µm) of the Pseudomonas aeruginosa biofilm
obtained by scanning confocal laser microscopy
The biofilm was negatively stained with 0.1% fluorescein. The horizontal sections show the
removal of out-of-focus information and reveal aspects of the internal structure of the
biofilm.
Reprinted with permission from [45] © American Society for Microbiology (1991).
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Figure 2. Bacterial biofilm formation and growth
(A) The four-step process involved in the formation of biofilms. (B) The lipoteichoic acid is
anchored to the cell membrane and extends out past the edge of the cell wall; it is the initial
molecular contact between the bacterium and other materials. (C) The chemical structure of
lipoteichoic acid.
Reprinted with permission from [46] © Elsevier (2008).
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Figure 3. Regulatory networks controlling the transition between planktonic and biofilm lifestyle
The external frames illustrate the bacterial envelope with one or two membranes according
to (C) Gram-positive and (A, B & D) Gram-negative bacteria, respectively. (A) Control of
biofilm formation in Pseudomonas aeruginosa through the two-component system GacS
(HK)/GacA (RR) mediated by sRNA rsmY and rsmZ gene transcription and modulated by
RetS and LadS, two additional HK in P. aeruginosa. (B) Control of exopolysaccaride
alginate in P. aeruginosa, which further impacts biofilm architecture by the system ECF σ
factor AlgU–anti-σ MucA–AlgP (IM)–AlgW (periplasmic) complex: (1) activation of
AlgW/AlgP; (2) cleavage of MucA; (3) release of AlgU; (4) activation of the alg
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UmucABCD operon. (C) Control of Staphylococcus aureus biofilm formation through the
Agr QS system: (1) AgrD autoinducer production; (2) AgrD autoinducer accumulation in
the extracellular medium where it reaches a threshold; (3) activation of the two-component
system AgrCA by AgrD at the threshold concentration; (4) AgrA-dependent activation of
the sRNA RNA III expression repressing expression of genes involved in biofilm formation
together with amplification loop of agrABCD. (D) Control of P. aeruginosa biofilm
formation through the intracellular second messenger c-di-GMP level controlled by the
FimX protein having DGC and PDE domains, a RR domain, and a PAS domain. Note that in
FimX protein, only PDE activity is detectable (continuous arrow), whereas DGC activity is
undetectable (dotted arrow).
DGC: Diguanylatecyclase; IM: Inner membrane; OM: Outer membrane; RR: Response
regulator.
Reprinted with permission from [264] © Springer (2011).
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Figure 4. Autoinducers and analogs
(A) Autoinducer-1 chemical structure and its analogs homocysteine derivative [105] and 3-
oxopentanoyl HSL [106].
(B) Autoinducer-2 chemical structure, its precursor DPD and its analogs ethyl-DPD [265]
and DHD (4S, 5R)-4 [266].
DPD: 4,5-dihydroxy-2,3-pentanedione.
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Figure 5. General protocols for an NMR metabolomics study
BMRB: Biological Magnetic Resonance Data Bank; HMDB: Human Metabolome Database;
HSQC: Heteronuclear single-quantum correlation; KEGG: Kyoto Encyclopedia of Genes
and Genomes; MMCD: Madison Metabolomics Consortium Database; OPLS-DA:
Orthogonal partial least squares discriminant analysis; PCA: Principal component analysis;
TOCSY: Total correlation spectroscopy.
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Figure 6. Hypothetical principal component analysis scores plot for several scenarios
(A) Inactive compound; (B) active and selective inhibitor; (C) active, nonselective inhibition
of target and secondary protein; and (D) active, nonselective preferential inhibition of
secondary protein.
PC: Prinicipal component.
Reprinted with permission from [267] © American Chemical Society (2006).
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Figure 7. 1H NMR spectra of the intracellular metabolic profiles of aqueous extract of MCF-7
cells
The sample used for spectrum contained approximately 6 × 105 cells. The spectra shown in
the inset were also plotted using the same expanded x-axis scale.
Ace: Acetate; Bet: Betaine; Cho: Choline; For: Formate; GSH: Glutathione; Lac: Lactate;
Myo: Myo-inositol; PCh: Phosphocholine; Pyr: Pyruvate; Suc: Succinate; TMAO:
Trimethylamine N-oxide; TSP: 3-trimethylsilylpropionic acid.
Reprinted with permission from [268] © Springer (2009).
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Figure 8. 2D NMR spectra obtained from metabolomics samples
(A) Overlay of 2D 1H–13C heteronuclear single-quantum correlation spectra comparing
wild-type Staphylococcus epidermidis strain 1457 (red) and aconitase mutant strain 1457-
acnA::tetM (black) grown for 6 h in standard tryptic soy broth media augmented with
0.25% 13C-glucose. NMR resonances corresponding to specific metabolites are labeled and
citrate is circled. (B) Overlay of 2D 1H–1H total correlation spectroscopy spectra comparing
wild-type S. epidermidis strain 1457 (red) and aconitase mutant strain 1457-acnA::tetM
(black) grown for 6 h in standard tryptic soy broth media.
Reprinted with permission from [124] © American Chemical Society (2011).
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Figure 9. Conceptual illustration of the principal component analysis of NMR-spectral data
Each 1D 1H NMR spectrum is converted into a single point in multidimensional space. Each
axis (e.g., V1, V2 and V3) corresponds to a chemical shift (ppm) and the value along the axis
is the peak intensity or bin integral. A vector (PC1) corresponds to the largest variation in
the data. The second vector (PC2) is orthogonal to the first vector and corresponds to the
second largest variation in the data. The scores correspond to the fit of each point (spectrum)
to each PC vector, where the resulting 2D scores plot identifies the relative similarities and
differences between the NMR spectra based on the clustering pattern.
PC: Prinicipal component; PCA: Principal component analysis.
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Figure 10. Staphylococcus epidermidis biofilm formation, regulated by the tricarboxylic acid
cycle
(A) 2D orthogonal partial least squares discriminant analysis (OPLS-DA) comparing wild-
type Staphylococcus epidermidis 1457 cells grown 6 h in standard tryptic soy broth media,
with S. epidermidis 1457 cells grown 6 h in iron-depleted media (DTSB), with the addition
of 4% ethanol, with the addition of 2% glucose, with the addition of 0.06 µg/ml tetracycline,
with the addition of 5% NaCl, and 6 h growth of aconitase mutant strain 1457-acnA::tetM in
standard tryptic soy broth media. The ellipses correspond to the 95% confidence limits from
a normal distribution for each cluster. For the OPLS-DA scores plot, the 6 h growth of wild-
type S. epidermidis 1457 was designated the control class and the remainder of the cells
were designated as treated. The OPLS-DA used one predictive component and four
orthogonal components to yield a R2X of 0.637, R2Y of 0.966 and Q2 of 0.941. (B)
Metabolomic tree diagram generated from the the 2D OPLS-DA scores plot depicted in (A).
Each node is labeled with the bootstrap number, where a value above 50 indicates a
statistically significant separation.
Reprinted with permission from [124] © American Chemical Society (2011).
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Figure 11. Cytoscape network depicting the metabolite concentration changes caused by the
inactivation of the tricarboxylic acid cycle
Nodes colored red correspond to metabolites with an increase in concentration due to
inactivated TCA cycle. Nodes colored green correspond to metabolites with a decrease in
concentration due to TCA cycle inactivation. Nodes colored blue correspond to metabolites
that are not observed in the NMR spectra, do not have a reference NMR spectrum (or
assignment) or did not exhibit a significant concentration change. Metabolic pathways are
labeled on the network.
ACA: Acetaldehyde; ACE: Acetate; ACP: Acetyl-P; AKG: α-ketoglutarate; ALAAc:
Acetyl-alanine; AMI: 4-aminobutanoate; CIR: Citrulline; CIT: Citrate; ETH: Ethanol; F6P:
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Fruc-6P; G1P: Gluc-1P; G6P: Gluc-6P; GAL: Galacturonic acid; GAL1P: R-D-gala-1P;
GLR: Glucuronate; GLS: D-glucosamine; GLS6P: Glucosamine-6P; GLSAc: N-Ac-D-
glucosamine; GLSAc6P: Acetyl-glucosamine-6P; GLUAc: Acetyl-glutamate; GLY:
Glyceraldehyde; ICI: Isocitrate; INO: Ino, Ade, Xan; LAC: Lactate; MANAc: N-acetyl-D-
mannosamine; MIN: Myo inositol; MSE: Selenomethionine; NEUAc: N-Ac-neuraminate;
ORN: Ornithine; ORNAc: Acetyl-ornithine; PEP: Phosphoenolpyruvic acid; PRO: Proline;
RIB: D-ribose; SAM: S-adenosyl-methionine; SER: Homoserine; SUCSER: O-Succinyl-L-
homoserine); TCA: Tricarboxylic acid; UDPGLR: UDP-glucoronate; UDPGLSAc: UDP-
NAc-D-glucosamine; VAL: Valine.
Reprinted with permission from [124]. © American Chemical Society (2011).
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Figure 12. Metabolome difference between Pseudomonas aeruginosa planktonic and biofilm cells
(A) PC analysis score plot for chemostat planktonic and biofilm cell samples for
Pseudomonas aeruginosa. (B) Loading plot of the first PC.
PC: Principal component.
Reprinted with permission from [149] © American Chemical Society (2007).
Zhang and Powers Page 51
Future Med Chem. Author manuscript; available in PMC 2013 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 13. NMR characterization of different Pseudomonas fluorescens biofilm cultures
(A) Partial least squares discriminant analysis (PLS-DA) scores plot of the metabolite
concentrations of Pseudomonas fluorescens CHA0 (black), CHA19 (red), SCV (green) and
WS (blue). Each data point represents a single extract and the position determined as a linear
combination of 32 metabolite concentrations obtained from the 1H NMR spectra. The four
strains could be separated along three components. (B) Killing curves of P. fluorescens
CHA0 (open squares), CHA19 (filled squares), SCV (closed circles) and WS (open circles).
Biofilms of each of the strains were exposed to a series of metal concentrations for 4 h
followed by viable cell counting. Shown are the log killing values, which are the number of
cells killed following the exposure to metal. Error bars represent standard deviation
calculated from four replicates. Average cell counts for the initial unexposed controls were
5.38 ± 0.47, 4.89 ± 0.45, 5.23 ± 0.39, 5.17 ± 0.47 log10 cfu peg−1 for CHA0, CHA19, SCV
and WS, respectively.
SCV: Small colony variants; WS: Wrinkly spreaders.
Reprinted with permission from reference [246]. © Wiley-Blackwell (2010).
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Figure 14. Hierarchical clustering analysis of control and copper-exposed biofilm and planktonic
culture metabolite concentrations
Identified metabolites were analyzed for any apparent patterns. Clustering was performed
using Pearson correlation as the distance metric. The cluster tree shows how the samples and
metabolites divide. The samples are shown across the top of the figure, labeled by their
class, and the metabolites are shown on the side. These were colored according to the
grouping pattern that they showed: green metabolites were only changing in the planktonic
cultures, red only in biofilms and blue were changing in both cultures in response to copper
exposure.
Reprinted with permission from reference [148]. © American Chemical Society (2011).
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Table 1
NMR software packages.
Software Operating system Source Dimension Ref.
ACDLab Win Commercial 1D and 2D [302]
CCPNmr Win/Mac/Unix Academic 2D [269,303]
Felix Win/Unix Commercial 2D [304]
FERCH Win Commercial 1D [305]
Gifa Unix Academic 1D and 2D [270,306]
iNMR Mac Commercial 1D and 2D [307]
matNMR Win/Mac/Unix Academic 1D and 2D [271,308]
MestreNova Win/Mac/Unix Commercial 1D and 2D [309]
NMRPipe Win/Mac/Unix Academic 2D [272,310]
NMRViewJ Win/Mac/Unix Commercial 2D [311]
NUTS Win Commercial 1D and 2D [312]
RMN Mac Academic 1D and 2D [313]
rNMR Win/Mac/Unix Academic 2D [273,314]
Sparky Win/Mac/Unix Academic 2D [315]
SpinWorks Win/Mac/Unix Academic 1D and 2D [316]
TARQUIN Win/Mac/Unix Academic Solid state [274,317]
WIN-NMR Win Commercial 1D [318]
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